Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DuCoRa-SCLC
2022-001822-31Phase 2Active
- Sponsor
- Saarland University
- Start
- Aug 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in small cell lung cancer (SCLC), sponsored by Saarland University. Primary endpoint: Feasibility of the treatment scheme until completion of all planned radiotherapy treatments. Started Aug 2022; status: active.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2022-001822-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001822-31.